Theravance Biopharma
TBPHTBPH · Stock Price
Historical price data
Overview
Theravance Biopharma is a commercial-stage biotech focused on transforming treatment for serious respiratory diseases through organ-selective medicines. Its core achievement is the FDA approval and commercialization of YUPELRI® (revefenacin) for COPD, validating its multivalent pharmacology platform. The company's strategy involves leveraging this platform to advance a pipeline of targeted respiratory therapeutics while managing commercial execution through a partnership with Viatris.
Technology Platform
Proprietary multivalent pharmacology platform focused on designing organ-selective small molecules that maximize therapeutic effect at the target site (e.g., lungs) while minimizing systemic exposure and side effects.
Pipeline
61| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Telavancin | End-Stage Renal Disease | Approved | |
| umeclidinium 62.5 µg and vilanterol 25 µg + Revefenacin 175 ... | COPD (Chronic Obstructive Pulmonary Disease) | Approved | |
| Ampreloxetine + Placebo | Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | |
| ampreloxetine + Placebo | Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | |
| ampreloxetine + Placebo | Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
Faces direct competition in the nebulized LAMA space from Sunovion's Lonhala Magnair® and indirect competition from dominant handheld LAMA and LAMA/LABA inhalers from giants like GSK, AstraZeneca, and Boehringer Ingelheim. Its platform competes with other approaches to lung-selective drug design.
